PAYX Form 4: 725 RSUs awarded; 3,061 options at $127.52
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Paychex (PAYX) reported an insider equity award on Form 4. A director acquired 725 shares of common stock via restricted stock units on 10/15/2025 at $0, increasing beneficial ownership to 79,344 shares directly.
The filing also shows a new stock option grant for 3,061 shares at an exercise price of $127.52 on 10/15/2025, first exercisable on 10/15/2026 and expiring on 10/14/2035. Existing option holdings remain outstanding across multiple grants, with exercise prices ranging from $57.20 to $140.68 and expirations extending through 2035. The RSU award is pursuant to the Amended and Restated 2002 Stock Incentive Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
VELLI JOSEPH M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 3,061 | $127.52 | $390K |
| Grant/Award | Common Stock | 725 | $0.00 | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
Holdings After Transaction:
Stock Option — 3,061 shares (Direct);
Common Stock — 79,344 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did PAYX disclose in this Form 4?
A director reported receiving 725 RSUs on 10/15/2025 at $0 and a new stock option grant for 3,061 shares at $127.52.
What are the terms of the new PAYX stock option grant?
Options for 3,061 shares at $127.52, first exercisable on 10/15/2026, expiring on 10/14/2035.
Was the PAYX equity award part of a stock plan?
Yes. The 725 RSUs were awarded pursuant to the Amended and Restated 2002 Stock Incentive Plan.
What other PAYX options are outstanding for the insider?
Multiple grants remain outstanding, with exercise prices from $57.20 to $140.68 and expirations through 2035.
What is the insider’s role at PAYX?
The reporting person is a Director of Paychex, Inc.